Aside from ibrutinib, individuals with M-CLL, devoid of TP53 aberrations and suit adequate to tolerate FCR therapy, should still be very good candidates for that latter, Using the benefit being this treatment could be finished in 6 months even though ibrutinib should be taken indefinitely. This feature could be notably useful for non-compliant clie… Read More